Exelixis and Ensysce report strong biotech advances, with Exelixis' cancer drug Cabometyx driving revenue growth and Ensysce's opioid-use-disorder drug PF9001 showing promise.
California approves State Farm's emergency request to raise homeowner insurance rates by an average of 17% after major wildfires, drawing criticism from consumer advocates.
Exelixis and Ensysce report strong biotech advances, with Exelixis' cancer drug Cabometyx driving revenue growth and Ensysce's opioid-use-disorder drug PF9001 showing promise.
California approves State Farm's emergency request to raise homeowner insurance rates by an average of 17% after major wildfires, drawing criticism from consumer advocates.
